Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
Read More
Tag: Jazz Pharmaceuticals
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Jazz will add GW’s plant-derived cannabinoid treatment Epidiolex to its roster
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
